Financial Daily from THE HINDU group of publications Tuesday, Nov 09, 2004 |
|
|
|
|
|
Corporate
-
People Alan Sheppard to head Dr Reddy's Europe generics business Our Bureau
Hyderabad , Nov. 8 DR Reddy's Laboratories Ltd has announced that Mr Alan Sheppard has joined the company as Executive Vice-President and Head of Europe Generics, and Managing Director and Head of Dr Reddy's UK Ltd. In a press release here on Monday, Dr Reddy's said Mr Sheppard would be responsible for the management of the company's generics business in Europe and would be based at the company's offices in UK. Commenting on development, the Dr Reddy's Chief Executive Officer, Mr G.V. Prasad, said, "Alan Sheppard brings with him a wealth of experience, which includes commercial, general management, R&D, manufacturing and strategic planning across generics, ethical branded, OTC and vaccines. Dr Reddy's will leverage this experience in taking our business forward in Europe." Mr Sheppard joins Dr Reddy's from Pliva, a leading European pharmaceutical company, where he was Vice-President for Global Corporate Strategy. He had previously been Vice-President, Western Europe, where he was responsible for establishing Pliva's business in the European Union. He also served as General Manager of Rhone-Poulenc Rorer (now Aventis); European marketing director for Medeva and held various positions with Institute Merieux, Smith Kline and Upjohn. According to the release, Mr Sheppard has served on several UK Government Committees and has been along standing member of the Association of British Pharmaceutical Industry's Code of Practice Committee, which regulates the promotion of medicines.
More Stories on : People | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|